Crossmark

Comparison of outcomes using the rituximab originator MabThera with the biosimilar Truxima in patients with ANCA-associated vasculitis

Crossref DOI link: https://doi.org/10.1080/03009742.2021.1926318

Published Online: 2021-09-02

Published Print: 2022-03-04

Update policy: https://doi.org/10.1080/tandf_crossmark_01

Authors

Antonelou, M

Abro, A

Heath, R

Iacovou, A

Ashley, C

Caplan, J

Morgan, MD

Logan, S

Harper, L

Salama, AD
License Information

License valid from 2021-09-02
More Information

Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.

Aim & Scope: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=irhe20

Publication History

Accepted: 2021-05-03

Published: 2021-09-02